Background: India is having the highest prevalence of diabetes. Diabetic retinopathy (DR) is a major microvascular complication of T2DM. HbA1c is a measure of average glycaemia during the prior 6–10 weeks. This study has been carried out to evaluate the impact of HbA1c on diabetic retinopathy. Methodology: Retrospective Cross sectional study, in Tertiary care centre in Gujarat. 1198 cases of diabetic retinopathy were evaluated from the medical records department and studied thoroughly for the study parameters. Sampling Technique was convenience Sampling. Results: We had a total of 780 males & 418 females in our study. Majority of the patients (51.50%) were from the age group of 40-59 years. Our study observed a majority of patients (96.24%) had Type2 DM, while rest (3.76%) had Type1 DM. We had majority of the patients (39.57%) with duration of DM of more than 10 years. Many patients in our study (38.98%) also had hypertension while few of them (8.18%) had Dyslipedemia. Majority of our study patients (78.80%) were diagnosed of not having diabetic retinopathy while the rest 21.20% were diagnosed of having the diabetic retinopathy. Significant correlation was seen between the types of diabetes, Hba1c levels and presence or absence of Diabetic retinopathy. With more number of cases of diabetic retinopathy in low sugar control and type 2 diabetes mellitus as compared to better sugar control patients (p < 0.001). Significant correlation was seen between the age groups, HbA1c levels and presence of diabetic retinopathy. With the advanced age and higher Hba1c levels, there are more chances of diabetic retinopathy (p < 0.001). Significant correlation was seen between the Hypertension, dyslipedemia & Hba1c in patients found positive for diabetic retinopathy with fundoscopic examination. This shows more chances of diabetic retinopathy in patients who have poor sugar control with other comorbidities. Many studies show similar results as our study. Conclusion: We encountered a 21.20% of patients had diabetic retinopathy. We conclude that strict sugar control is necessary in preventing the diabetic retinopathy along with a watch on modifiable risk factors.
Springer SC, Silverstein J, Copeland K, Moore KR, Prazar GE, Raymer T, et al.; American Academy of Pediatrics. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013 Feb; 131(2):e648–64.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017 Jun; 128: 40–50.
Federation ID. IDF diabetes atlas eighth edition 2017. 43-45.
Xie X, Xu L, Jonas J, Wang Y. Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing Eye Study. Eur J Ophthalmol. 2009;19(1):91.
Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients—a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;8(1):1.
Ruta L, Magliano D, LeMesurier R, Taylor H, Zimmet P, Shaw J. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med. 2013;30(4):387–98
Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet 2010;376:124–36.
International Diabetes Federation. Diabetes atlas. 7th edition. Brussels, Belgium: International Diabetes Federation, 2015.
Yau JWY, Rogers SL, Kawasaki R. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64.
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision 2015;2:17.
Sivaprasad S, Gupta B, Gulliford MC, et al. Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (drive UK). PLoS ONE 2012;7:e32182.
Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications–the Link¨oping Diabetes Complications Study. Pediatr Diabetes 2009;10:168–176
Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:25868.
Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (part 1). Diabetes Care 1978;1:16888.
Adler AI, Boyko EJ, Ahroni AJ, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle prospective diabetic foot study. Diabetes Care 1997;20:11627.
UKPDS Group. Risk factors for coronary artery disease in noninsulin dependent diabetes (UKPDS 23). BMJ 1998;316:8238.
Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:9607.
Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Predictors of stroke in middleaged patients with noninsulindependent diabetes. Stroke 1996;27:638.
Standl E, Balletshofer B, Dahl B,Weichenhain B, Stiegler H, Hormann A, et al. Predictors of 10year macrovascular and overall mortality in patients with NIDDM: the Munich general practitioner project. Diabetologia 1996;39:15405.
Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999;116:213.
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Tenyear cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (noninsulin dependent) diabetic and nondiabetic subjects. Diabetologia 1993;36:117584.
Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle aged nondiabetic men. Diabetes Care 1998;21:3607.
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: theWhitehall study. BMJ 1983;287:86770.
Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet 1976;ii:100912.
Pettitt DJ, Knowler WC, Lisse JR, Bennett PH. Development of retinopathy and proteinuria in relation to plasma glucose concentration in Pima Indians. Lancet 1980;ii:10502.
Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005; 36(3):232–40.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.
Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K DETECT- Collaboration Writing Group. Glycemic thresholds for diabetes-specific retinopathy: Implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145–50.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713–20.
ACCORD Study Group; ACCORD Eye Study Group. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. the effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology. 2014;121:2443–51.